Sequent Scientific Limited (SEQUENT) AI Stock Analysis

• Market Cap: ₹56.17B
• Dividend Yield: N/A
• Average Volume (3M): 119.95K
• Price to Earnings (P/E): 133.0
• Beta (1Y): 1.39
• Revenue Growth: 14.39%
• EPS Growth: 152.14%
• Country: IN
• Employees: 1,195
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.59
• Shares Outstanding: 252,949,340
• 10 Day Avg. Volume: 209,903
• 30 Day Avg. Volume: 119,946
• PEG Ratio: -0.99
• Price to Book (P/B): 4.96
• Price to Sales (P/S): 2.25
• P/FCF Ratio: 78.97
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 677.97
• Revenue Forecast (FY): ₹1.47T

• Rating: 58 Neutral
• Price Target: ₹258.00 ▲(15.54% Upside)

Sequent Scientific Limited's overall stock score is primarily influenced by its strong financial recovery and positive technical indicators. However, the high P/E ratio suggests potential overvaluation, which is a significant risk factor. The absence of earnings call insights and corporate events means these factors did not contribute to the score.

Positive Factors

Profitability Recovery

The turnaround in profitability indicates effective cost management and operational improvements, enhancing long-term financial stability.

Cash Flow Management

Improved cash generation supports ongoing operations and strategic investments, crucial for sustaining growth and financial health.

Operational Efficiency

Higher margins reflect better cost control and pricing power, contributing to stronger competitive positioning and profitability.

Negative Factors

Modest Revenue Growth

Slower revenue expansion may limit market share gains and scale benefits, potentially impacting long-term growth prospects.

Debt Management

While leverage is moderate, rising debt levels could strain resources if not managed, affecting financial flexibility and risk profile.

Free Cash Flow Reliability

Inconsistent cash flow generation could challenge funding for expansion and innovation, affecting long-term strategic initiatives.

Sequent Scientific Limited Business Overview & Revenue Model

Company Description

Sequent Scientific Limited (SEQUENT) is a leading integrated pharmaceutical company based in India, specializing in the development, manufacturing, and marketing of veterinary and pharmaceutical products. The company operates primarily in the animal health sector, offering a diverse range of products including formulations, active pharmaceutical ingredients (APIs), and contract manufacturing services. Sequent serves both domestic and international markets, focusing on enhancing the health and well-being of animals while also contributing to food safety and quality in the agricultural sector.

How the Company Makes Money

Sequent Scientific generates revenue through multiple streams, primarily from the sale of its veterinary pharmaceuticals and formulations. The company’s core revenue model is based on manufacturing and selling a variety of animal health products, which includes both product sales and contract manufacturing services for other pharmaceutical companies. Significant partnerships with global players in the veterinary sector enhance its market reach and product offerings. Additionally, Sequent benefits from strategic collaborations and licensing agreements that expand its product portfolio and market access, ultimately contributing to its overall earnings.

Sequent Scientific Limited Financial Statement Overview

Summary

Sequent Scientific Limited has demonstrated a substantial recovery in profitability and cash flow management. The improvement in net income and gross profit margin indicates enhanced operational efficiency. However, modest revenue growth and stable leverage ratios suggest a need for strategic expansion and careful debt management.

Income Statement

Sequent Scientific Limited showed a strong recovery in net income from a loss of 358.69 million to a profit of 218.8 million in the latest year, demonstrating significant improvement in profitability. The gross profit margin improved to 47.7% in 2025, a notable increase from 40.5% in 2024. However, the revenue growth rate from 2024 to 2025 was modest at 13.5%, and the EBIT margin was strong at 29.5% in 2025. This indicates a return to operational profitability but highlights slower revenue expansion.

Balance Sheet

The company's debt-to-equity ratio remained stable around 0.68, reflecting moderate leverage. The return on equity (ROE) improved to 3.1% from a negative ROE in the previous year, showing a turnaround in profitability. The equity ratio was 44.0%, suggesting a balanced capital structure. However, the increase in total debt over the past years may pose potential risks if not managed carefully.

Cash Flow

The operating cash flow to net income ratio improved significantly, reflecting improved cash generation relative to profitability. Free cash flow saw a significant rise from negative in 2024 to 442.7 million in 2025, indicating better cash management. However, the free cash flow growth rate is not reliable due to prior negative figures, and consistent positive free cash flow will be essential for financial health.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	16.03B	15.51B	13.66B	14.18B	14.10B	13.52B
Gross Profit	7.70B	7.40B	5.53B	1.59B	5.66B	6.15B
EBITDA	1.80B	1.59B	549.80M	-464.48M	1.18B	2.06B
Net Income	296.80M	218.80M	-358.69M	-1.21B	409.55M	954.42M
Balance Sheet
Total Assets	0.00	16.02B	15.40B	15.29B	14.51B	13.93B
Cash, Cash Equivalents and Short-Term Investments	630.78M	691.40M	687.85M	416.25M	591.21M	597.03M
Total Debt	0.00	4.81B	4.88B	4.44B	3.65B	2.77B
Total Liabilities	-7.70B	8.32B	8.27B	7.80B	7.11B	6.16B
Stockholders Equity	7.70B	7.04B	6.57B	6.99B	6.92B	7.28B
Cash Flow
Free Cash Flow	0.00	442.70M	-2.12M	-693.71M	-18.69M	619.24M
Operating Cash Flow	0.00	833.60M	305.95M	168.08M	305.95M	1.15B
Investing Cash Flow	0.00	-247.80M	-119.05M	-649.58M	-955.66M	96.48M
Financing Cash Flow	0.00	-607.30M	45.46M	322.28M	672.57M	-1.39B

Sequent Scientific Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 223.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SEQUENT, the sentiment is Positive. The current price of 223.3 is below the 20-day moving average (MA) of 227.64, above the 50-day MA of 213.06, and above the 200-day MA of 179.41, indicating a neutral trend. The MACD of 4.29 indicates Positive momentum. The RSI at 50.40 is Neutral, neither overbought nor oversold. The STOCH value of 12.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SEQUENT.

Sequent Scientific Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADVENZYMES	65 Neutral	₹35.12B	25.64	―	1.68%	14.11%	7.47%
AARTIDRUGS	62 Neutral	₹39.13B	19.65	―	0.24%	4.08%	31.52%
SEQUENT	58 Neutral	₹56.17B	132.97	―	―	14.39%	152.14%
GLENMARK	53 Neutral	₹521.13B	69.14	―	0.26%	30.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SPARC	41 Neutral	₹44.39B	-14.87	―	―	-0.82%	34.67%

Sequent Scientific Limited Corporate Events

Sequent Scientific Limited Announces Merger Scheme with Key Industry Players

Sequent Scientific Limited has announced a merger scheme involving several companies, including Symed Labs Limited and Viyash Life Sciences Private Limited. The National Company Law Tribunal (NCLT) has sanctioned this scheme, and a share exchange ratio has been established, where Viyash will issue 47 equity shares for every 1 equity share of Geninn Life Sciences Private Limited. This merger is expected to consolidate operations and enhance market positioning for the involved entities.

SeQuent Scientific and Viyash Lifesciences Merger Approved by NCLT

SeQuent Scientific Limited and Viyash Lifesciences have received approval from the National Company Law Tribunal for their merger, marking a significant transformation in the global animal health market. The merger is expected to create a leading animal health powerhouse, leveraging synergies to enhance financial performance and capitalize on growth opportunities in the fast-growing companion animal health segment and the genericization of animal health. This strategic move aims to accelerate organic growth, enhance financial resilience, and position the combined entity as a world-class provider of innovative animal health solutions.

Sequent Scientific and Viyash Lifesciences Secure NCLT Approval for Transformative Merger

Sequent Scientific Limited and Viyash Lifesciences Private Limited have received approval from the National Company Law Tribunal for their merger, marking a significant transformation in the global animal health market. This merger is expected to create a leading animal health company from India, leveraging synergies to enhance financial performance and capitalize on growth opportunities in the companion animal health segment and the genericization of animal health products. The merger aims to accelerate organic growth, provide financial stability, and enhance capabilities in research and development, positioning the combined entity as a reliable partner in the industry.

Sequent Scientific and Viyash Lifesciences Merger Approved, Set to Transform Animal Health Market

Sequent Scientific Limited and Viyash Lifesciences have received approval from the National Company Law Tribunal for their merger, marking a significant transformation in the global animal health market. The merger is expected to create a leading animal health powerhouse, leveraging combined strengths to enhance growth opportunities in the companion animal health segment and generic animal health products, while also boosting financial resilience and operational capabilities.

Sequent Scientific Releases Q2 FY26 Financial Results

Sequent Scientific Limited has published its unaudited financial results for the quarter and half-year ending September 30, 2025, in The Financial Express and Nava Telangana newspapers. This announcement is part of the company’s regulatory compliance with the Securities and Exchange Board of India, ensuring transparency and accessibility of financial information to stakeholders.

Sequent Scientific Limited Reports Financial Results for Q2 2025

Sequent Scientific Limited announced the approval of its unaudited standalone and consolidated financial results for the quarter and half-year ending September 30, 2025, during a board meeting. The results, reviewed by independent auditors, indicate the company’s continued financial performance and compliance with regulatory standards, potentially impacting its operational strategies and stakeholder interests positively.

Sequent Scientific to Rebrand Post-Merger

Sequent Scientific Limited has announced a proposal to change its name to reflect a unified identity following a merger with multiple life sciences companies. The new name will incorporate ‘Viyash’ to leverage the brand equity of the Viyash group, pending necessary approvals and the effectiveness of the merger scheme.

Sequent Scientific Completes Postal Ballot Dispatch and Prepares for Trading

Sequent Scientific Limited announced the completion of the dispatch of its Postal Ballot Notice, as confirmed by newspaper advertisements in Financial Express and Nava Telangana. The company has also finalized the basis of allotment for its equity shares, with trading set to commence on October 6, 2025, following approval from NSE Emerge. This development marks a significant step in the company’s financial operations, potentially impacting its market presence and stakeholder engagement.